BRPI0512864A - composições e métodos para o tratamento de condições e desordens oculares - Google Patents

composições e métodos para o tratamento de condições e desordens oculares

Info

Publication number
BRPI0512864A
BRPI0512864A BRPI0512864-1A BRPI0512864A BRPI0512864A BR PI0512864 A BRPI0512864 A BR PI0512864A BR PI0512864 A BRPI0512864 A BR PI0512864A BR PI0512864 A BRPI0512864 A BR PI0512864A
Authority
BR
Brazil
Prior art keywords
compositions
methods
disorders
eye conditions
treating eye
Prior art date
Application number
BRPI0512864-1A
Other languages
English (en)
Inventor
Reza Dana
Debra Schaumberg
Frank Molock
Lenora Copper
Shiv Mahadevan
Kathy Osborn Lorenz
Saadia Rashid
Original Assignee
Schepens Eye Res
Johnson & Johnson Vision Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35784207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512864(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schepens Eye Res, Johnson & Johnson Vision Care filed Critical Schepens Eye Res
Publication of BRPI0512864A publication Critical patent/BRPI0512864A/pt
Publication of BRPI0512864B1 publication Critical patent/BRPI0512864B1/pt
Publication of BRPI0512864B8 publication Critical patent/BRPI0512864B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES E MéTODOS PARA O TRATAMENTO DE CONDIçõES E DESORDENS OCULARES. A presente invenção refere-se a composições ácidos graxos de ómega 6 e/ou de ómega 3 e seus usos. A presente invenção também refere-se a métodos de tratamento de uso de tais composições.
BRPI0512864A 2004-07-01 2005-06-30 composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição BRPI0512864B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58451404P 2004-07-01 2004-07-01
US60/584,514 2004-07-01
PCT/US2005/023113 WO2006007510A1 (en) 2004-07-01 2005-06-30 Compositions and methods for treating eye disorders and conditions

Publications (3)

Publication Number Publication Date
BRPI0512864A true BRPI0512864A (pt) 2008-04-08
BRPI0512864B1 BRPI0512864B1 (pt) 2021-04-27
BRPI0512864B8 BRPI0512864B8 (pt) 2021-05-25

Family

ID=35784207

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512864A BRPI0512864B8 (pt) 2004-07-01 2005-06-30 composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição

Country Status (15)

Country Link
US (2) US20060009522A1 (pt)
EP (1) EP1781278B2 (pt)
JP (1) JP2008505177A (pt)
KR (1) KR20070040381A (pt)
CN (1) CN101043884A (pt)
AU (1) AU2005262392A1 (pt)
BR (1) BRPI0512864B8 (pt)
CA (1) CA2572344A1 (pt)
IL (1) IL180342A0 (pt)
MX (1) MX2007000208A (pt)
NO (1) NO20070561L (pt)
NZ (1) NZ552481A (pt)
RU (1) RU2007103835A (pt)
WO (1) WO2006007510A1 (pt)
ZA (1) ZA200700918B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
AU2005296212A1 (en) * 2004-10-19 2006-04-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Topical treatment with NGF and DHA in damaged corneas
US20070293410A1 (en) * 2006-06-15 2007-12-20 Surowiak Richard J Contact lens and method for preventing contact lens intolerance
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CA2704371A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
MX358504B (es) 2009-06-05 2018-08-21 Allergan Inc Lagrimas artificiales y usos terapeuticos.
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
DE102010050570A1 (de) * 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012067224A1 (ja) * 2010-11-19 2012-05-24 日本水産株式会社 角膜上皮障害及び／又は結膜上皮障害の治療又は予防剤
WO2012145119A2 (en) * 2011-04-17 2012-10-26 Michael Gurin Low inflammatory blended oils
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
JP6023181B2 (ja) 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US9381183B2 (en) * 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US20160310456A1 (en) * 2013-03-12 2016-10-27 Physicians Recommended Nutriceuticals, Llc Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
WO2013037794A1 (en) * 2011-09-12 2013-03-21 Georgiou Tassos Use of omega fatty acids for treating disease
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
JP6359517B2 (ja) 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−３脂肪酸エステル組成物
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
EP2664330A1 (de) 2012-05-15 2013-11-20 F. Holzer GmbH Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan
MX2015002208A (es) * 2012-08-31 2015-05-08 Bausch & Lomb Composiciones oftalmicas con acidos grasos omega-3.
US8673325B1 (en) * 2012-09-06 2014-03-18 Dignity Sciences Limited Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
WO2014132162A1 (en) 2013-02-26 2014-09-04 Belkin Laser Ltd. System for glaucoma treatment
PT3024484T (pt) 2013-07-23 2018-10-24 Novaliq Gmbh Composições de anticorpo estabilizadas
WO2015042442A1 (en) * 2013-09-19 2015-03-26 Dignity Sciences Limited Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
JP6768653B2 (ja) 2014-11-25 2020-10-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安定したオメガ−３眼科用組成物
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CN106963728A (zh) * 2016-01-13 2017-07-21 汤欣 一种二十二碳六烯酸结膜下注射液的制备方法及其应用
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP4374851B1 (en) 2016-12-23 2026-04-15 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
SG11202007860XA (en) 2018-03-28 2020-09-29 Novaliq Gmbh Pharmaceutical composition comprising timolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
NO345574B1 (en) 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
ES2982698T3 (es) * 2020-01-23 2024-10-17 Visufarma S P A Composición oftálmica para el tratamiento de la enfermedad del ojo seco
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
WO2022197960A1 (en) * 2021-03-18 2022-09-22 Jenivision Inc. Methods and compositions for treating eye diseases

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437014A (en) * 1890-09-23 Swing
US3572913A (en) * 1969-02-03 1971-03-30 Boylston Res Ass Comprehensive support for ophthalmic examination apparatus and instruments
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US4401372A (en) * 1972-10-02 1983-08-30 Syntex (U.S.A.) Inc. Contact lens
US4180308A (en) * 1972-10-02 1979-12-25 Syntex (Usa) Inc. Contact lens
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
DE2309440A1 (de) * 1973-02-26 1974-09-05 Katz Verfahren zum isolieren von lysozym
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4313355A (en) * 1978-02-06 1982-02-02 Syntex (U.S.A.) Inc. Method and apparatus for manufacturing plastic lenses
US4202226A (en) * 1978-02-06 1980-05-13 SyntexLaboratories, Inc. Method and apparatus for manufacturing plastic lenses
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4338419A (en) * 1979-02-09 1982-07-06 Syntex (U.S.A.) Inc. Process for treatment of hydrogel lens with thiols
US4379864A (en) * 1979-02-09 1983-04-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4543371A (en) * 1981-03-05 1985-09-24 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US5145686A (en) * 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
EP0092076B1 (fr) 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Composition lipidique destinée à l'alimentation orale, entérale ou parentérale
US4421748A (en) * 1982-07-13 1983-12-20 Trager Seymour F Artificial tear aid
US4678698A (en) * 1983-04-12 1987-07-07 Minnesota Mining And Manufacturing Company Contact lens cleaning article
US4533399A (en) * 1983-04-12 1985-08-06 Minnesota Mining And Manufacturing Company Contact lens cleaning method
US4622258A (en) * 1983-04-12 1986-11-11 Minnesota Mining And Manufacturing Company Contact lens cleaning article
JPS6158539A (ja) * 1984-08-29 1986-03-25 Nisshin Oil Mills Ltd:The スナツク様菓子の製造法
US4613380A (en) * 1985-04-01 1986-09-23 Dow Corning Corporation Method for removing lipid deposits from contact lenses
US5484432A (en) * 1985-09-27 1996-01-16 Laser Biotech, Inc. Collagen treatment apparatus
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5240701A (en) * 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5240702A (en) * 1986-05-15 1993-08-31 Emory University Method of treating stroke
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) * 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
CA1263270A (en) * 1987-08-19 1989-11-28 Bruce J. Holub Animal feed supplement
US5225374A (en) * 1988-05-13 1993-07-06 The United States Of America As Represented By The Secretary Of The Navy Method of fabricating a receptor-based sensor
US5111221A (en) * 1988-05-13 1992-05-05 United States Of America As Represented By The Secretary Of The Navy Receptor-based sensor
US4923700A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Artificial tear suspension
US4959048A (en) * 1989-01-17 1990-09-25 Helix Medical, Inc. Lacrimal duct occluder
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5278142A (en) * 1989-03-20 1994-01-11 Orbon Corporation Systemic delivery of polypeptides through the eye
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5206298A (en) * 1989-12-19 1993-04-27 Tomei Sangyo Kabushiki Kaisha Graft copolymer, solution containing the graft copolymer for treating contact lens, and method of treating contact lens with the solution and making hydrophilic lens surface
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
EP0459148B1 (en) * 1990-05-29 1996-01-03 Ocular Research Of Boston Inc. Dry eye treatment composition
US5167323A (en) * 1990-08-09 1992-12-01 Tomei Sangyo Co., Ltd. Lens treating device for treating contact lens
US5181604A (en) * 1990-09-14 1993-01-26 Tomei Sangyo Co., Ltd. Contact lens holder and treating device
US5203337A (en) * 1991-05-08 1993-04-20 Brigham And Women's Hospital, Inc. Coronary artery imaging system
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5469867A (en) * 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
PH30249A (en) * 1992-09-16 1997-02-05 Zhejiang Provincial Hospital O Neutral lipids from endosperm of job's tears
JPH06122627A (ja) * 1992-10-13 1994-05-06 Sagami Chem Res Center 抗アレルギー点眼液
US5378488A (en) * 1993-06-10 1995-01-03 Abbott Laboratories Aseptic processing of infant formula
AU1520095A (en) * 1993-12-29 1995-07-17 Bausch & Lomb Incorporated Carbohydrate composition and method for cleaning and disinfecting contact lenses
US6060644A (en) * 1994-03-24 2000-05-09 Iowa State University Research Foundation, Inc. Isolation and use of cuticular lipid genes
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5861148A (en) * 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
US6113894A (en) * 1995-01-23 2000-09-05 Smith; S. Gregory Ophthalmic compositions and process of using
DE69629230D1 (de) * 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
US5738856A (en) * 1995-11-03 1998-04-14 Ocular Research Of Boston, Inc. Skin care preparation and method
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
AU3692097A (en) * 1996-08-02 1998-02-25 Plum Kemi Produktion A/S An oil-in-water emulsion for use on human skin for cleansing, preserving or improving the condition of the skin
KR19990071477A (ko) * 1996-09-20 1999-09-27 아테로제닉스, 인코포레이티드 염증성질환의진단방법및매개체
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
JPH10218760A (ja) 1997-02-04 1998-08-18 Nobel Igaku Kenkyusho:Kk ドライアイ治療用の微量油添加目薬
WO1998039025A2 (en) * 1997-03-03 1998-09-11 Adcock Ingram Limited A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
US6107365A (en) * 1997-09-03 2000-08-22 The Regents Of The University Of California Biomimetic hydrogel materials
US6475784B1 (en) * 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
EP1082966A4 (en) 1998-05-15 2004-07-21 Wakamoto Pharma Co Ltd ANTI-INFLAMMATORY EYE DROPS
US6346594B1 (en) * 1998-09-21 2002-02-12 Menicon Co., Ltd. Ocular lens material and process for producing same
EP1156809B1 (en) * 1999-03-01 2005-12-07 Vista Scientific LLC Mucin containing ophthalmic preparations
US6429194B1 (en) * 1999-03-01 2002-08-06 Vista Scientific Llc Mucin containing ophthalmic preparation
US6428502B1 (en) * 1999-06-25 2002-08-06 Alcon Manufacturing, Ltd. Punctal cannula
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
AUPQ228199A0 (en) 1999-08-18 1999-09-09 Sly, Anthony William Ophthalmic fluid
WO2001028518A1 (de) * 1999-10-20 2001-04-26 Vesifact Ag Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen
US6286955B1 (en) * 1999-12-15 2001-09-11 Tetsuya Sakai Biocompatible lens, and method of producing the same
US6344047B1 (en) * 2000-02-02 2002-02-05 Eagle Vision Instrument for inserting a punctum plug and method for manufacturing the instrument
US6533415B2 (en) * 2000-03-21 2003-03-18 Menicon Co., Ltd. Ocular lens material having hydrophilic surface and process for preparing the same
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
WO2002009803A1 (en) * 2000-08-01 2002-02-07 Ocular Research Of Boston, Inc. Visual discomfort relief
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6667047B2 (en) * 2001-07-27 2003-12-23 International Flute Technologies Ltd Ultra-stable composition comprising moringa oil and its derivatives and uses thereof
ATE399562T1 (de) * 2001-08-23 2008-07-15 Westgate Biolog Ltd Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen
US20040076691A1 (en) 2002-01-16 2004-04-22 David Haines Anti-inflammatory formulations
US20040048926A1 (en) * 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
JP2005529945A (ja) * 2002-06-17 2005-10-06 リソルヴィックス ファーマシューティカルズ オメガ−３ｐｕｆａ由来の脂質メディエーターの類似体及び使用方法
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
AU2003259145A1 (en) 2002-07-17 2004-02-02 Spencer P. Thornton Treatment for dry eye syndrome
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
JP2005008570A (ja) * 2003-06-19 2005-01-13 Santen Pharmaceut Co Ltd 角膜疾患治療剤
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface

Also Published As

Publication number Publication date
CA2572344A1 (en) 2006-01-19
CN101043884A (zh) 2007-09-26
KR20070040381A (ko) 2007-04-16
MX2007000208A (es) 2007-08-07
NZ552481A (en) 2008-12-24
EP1781278A4 (en) 2009-09-02
EP1781278B2 (en) 2019-10-16
IL180342A0 (en) 2007-07-04
NO20070561L (no) 2007-03-30
AU2005262392A1 (en) 2006-01-19
EP1781278A1 (en) 2007-05-09
RU2007103835A (ru) 2008-08-10
JP2008505177A (ja) 2008-02-21
US20060009522A1 (en) 2006-01-12
WO2006007510A1 (en) 2006-01-19
EP1781278B1 (en) 2016-08-10
ZA200700918B (en) 2008-10-29
BRPI0512864B1 (pt) 2021-04-27
US20080153909A1 (en) 2008-06-26
BRPI0512864B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BRPI0512864A (pt) composições e métodos para o tratamento de condições e desordens oculares
BRPI0613358A8 (pt) ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
BR112012018246A2 (pt) compostos de amida reversa como inibidores de proteína desacetilase e métodos de uso destes
ATE443758T1 (de) Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
BR0312232A (pt) Inibidores de caspases e seus usos
PT1660507E (pt) Inibidores de proteassoma e seus métodos de utilização
WO2004106492A3 (en) Bicyclicpyrimidones and their use to treat diseases
TR200500221T2 (tr) Farmasötik Maddeler Olarak Bisiklik Amino Asitler
BRPI0606690A2 (pt) composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
CO6341640A2 (es) \\\"tratamiento de enfermedad autoinmunitaria e inflamatoria\\\"
ECSP077170A (es) Moduladores de receptores acetilcolina nicotinicos alfa 7 y sus usos terapeuticos
DE60316542D1 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
ATE461697T1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
PT1648484E (pt) Formulações para o tratamento de distúrbios artríticos
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2729 DE 25-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.